NEWS & EVENTS

14th Annual World Cancer Congress

July 22-24, 2023

Biolexis Therapeutics CSO invited to Chair Cancer Immunology & Immunotherapy session and present MolecuLern technology at 14th Annual World Cancer Congress – WCC 11: Cancer Immunology & Immunotherapy on July 22-24, 2023, at Barcelona, Spain.

WCC-2022 (bitcongress.com)

AACR 2022 Annual Meeting

April 8-13, 2023

Biolexis Therapeutics Inc., a leader in bio-tech research and creator of the FIELDS™ process, today announced that data highlighting an orally available, CDK9 selective small molecule inhibitor showing promise in n-Myc-driven neuroendocrine prostate cancers (NEPC) was presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.

https://www.pr.com/press-release/859029

AACR (American Association of Cancer Research) Annual Meeting

April 8-13, 2023

Biolexis management participated and presented pre-clinical data on CDK9 inhibitor at the AACR (American Association of Cancer Research) Annual Meeting on April 8-13, 2022, Ernest N. Morial Convention Center New Orleans, Louisiana.

B137 / 13 – Orally available, CDK9 selective, small molecule inhibitors shows promise in n-Myc-driven neuroendocrine prostate cancers (NEPC)

Session LBPO.MCB02 – Late-Breaking Research: Molecular/Cellular Biology and Genetics 2.

Next Generation Kinase Inhibitors Summit

February 22-23, 2023

Biolexis Therapeutics Business Development team participated 2nd Next Generation Kinase Inhibitors Summit was held on February 22-23, 2023, in Boston.

10th Annual Drug Discovery Strategic Summit

Oct 27-28, 2023

Biolexis Therapeutics Management participates and presents their MolecuLern technology at 10th Drug Discovery Strategic Summit, Oct 27th – 28th 2022, San Francisco CA, US